Myxobacteria-Derived Outer Membrane Vesicles: Potential Applicability Against Intracellular Infections.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Kiemer, Alexandra K
MetadataShow full item record
AbstractIn 2019, it was estimated that 2.5 million people die from lower tract respiratory infections annually. One of the main causes of these infections is Staphylococcus aureus, a bacterium that can invade and survive within mammalian cells. S. aureus intracellular infections are difficult to treat because several classes of antibiotics are unable to permeate through the cell wall and reach the pathogen. This condition increases the need for new therapeutic avenues, able to deliver antibiotics efficiently. In this work, we obtained outer membrane vesicles (OMVs) derived from the myxobacteria Cystobacter velatus strain Cbv34 and Cystobacter ferrugineus strain Cbfe23, that are naturally antimicrobial, to target intracellular infections, and investigated how they can affect the viability of epithelial and macrophage cell lines. We evaluated by cytometric bead array whether they induce the expression of proinflammatory cytokines in blood immune cells. Using confocal laser scanning microscopy and flow cytometry, we also investigated their interaction and uptake into mammalian cells. Finally, we studied the effect of OMVs on planktonic and intracellular S. aureus. We found that while Cbv34 OMVs were not cytotoxic to cells at any concentration tested, Cbfe23 OMVs affected the viability of macrophages, leading to a 50% decrease at a concentration of 125,000 OMVs/cell. We observed only little to moderate stimulation of release of TNF-alpha, IL-8, IL-6 and IL-1beta by both OMVs. Cbfe23 OMVs have better interaction with the cells than Cbv34 OMVs, being taken up faster by them, but both seem to remain mostly on the cell surface after 24 h of incubation. This, however, did not impair their bacteriostatic activity against intracellular S. aureus. In this study, we provide an important basis for implementing OMVs in the treatment of intracellular infections.
CitationCells. 2020 Jan 12;9(1). pii: cells9010194. doi: 10.3390/cells9010194.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Biocompatible bacteria-derived vesicles show inherent antimicrobial activity.
- Authors: Schulz E, Goes A, Garcia R, Panter F, Koch M, Müller R, Fuhrmann K, Fuhrmann G
- Issue date: 2018 Nov 28
- Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.
- Authors: Bottero D, Zurita ME, Gaillard ME, Bartel E, Vercellini C, Hozbor D
- Issue date: 2018 Feb 15
- Inflammasome Activation by Bacterial Outer Membrane Vesicles Requires Guanylate Binding Proteins.
- Authors: Finethy R, Luoma S, Orench-Rivera N, Feeley EM, Haldar AK, Yamamoto M, Kanneganti TD, Kuehn MJ, Coers J
- Issue date: 2017 Oct 3
- Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles enhance immunomodulation and antimicrobial activity in RAW264.7 macrophages.
- Authors: Hu R, Lin H, Li J, Zhao Y, Wang M, Sun X, Min Y, Gao Y, Yang M
- Issue date: 2020 Aug 27
- Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for <i>Staphylococcus aureus</i> vaccine.
- Authors: Irene C, Fantappiè L, Caproni E, Zerbini F, Anesi A, Tomasi M, Zanella I, Stupia S, Prete S, Valensin S, König E, Frattini L, Gagliardi A, Isaac SJ, Grandi A, Guella G, Grandi G
- Issue date: 2019 Oct 22